The short answer: Mounjaro (tirzepatide) slows how fast your stomach empties, and that is part of how it works. Large insurance-claims studies link GLP-1 based drugs, including tirzepatide, to a higher risk of a gastroparesis diagnosis, but the absolute risk is about 1% per year or less. The FDA label says Mounjaro is not recommended for people who already have severe gastroparesis.

What is gastroparesis, and how is it different from normal slowing?

Gastroparesis means the stomach empties too slowly even though nothing is blocking it. People often call it "stomach paralysis," but the stomach still moves. It just moves food on too slowly.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists these symptoms:

  • Feeling full soon after you start a meal, or long after you finish one
  • Nausea and vomiting
  • Too much bloating or belching
  • Pain in the upper abdomen, heartburn, and poor appetite

NIDDK names diabetes as the most common known cause. High blood sugar over many years can damage the vagus nerve, which controls the stomach muscles. This matters for Mounjaro users, because many already have type 2 diabetes before they start.

NIDDK also notes that some medicines slow stomach emptying and cause symptoms "similar to those of gastroparesis." That is the key distinction. A drug effect that fades when the drug clears is different from nerve damage that lasts.

Does Mounjaro slow stomach emptying?

Yes. The Mounjaro prescribing information states plainly that "tirzepatide delays gastric emptying." It also says "the delay is largest after the first dose and this effect diminishes over time."

The label gives a concrete example. After a first 5 mg dose, peak blood levels of acetaminophen (taken by mouth) dropped by 50% and arrived 1 hour later. By week 4, there was no meaningful effect on acetaminophen levels. This fading effect is called tachyphylaxis.

A 2024 review in the Journal of Clinical Endocrinology and Metabolism describes the same pattern across GLP-1 receptor agonists and tirzepatide. The authors note that slower emptying helps limit blood sugar spikes after meals. They also note the downside: food can stay in the stomach longer than expected, which matters before endoscopy or anesthesia. Our guide to Mounjaro before surgery covers that risk in detail.

What does the FDA label say about severe stomach problems?

The label has a warning section called "Severe Gastrointestinal Adverse Reactions." In the pooled placebo-controlled trials, severe stomach and bowel side effects occurred in:

  • 1.3% of people on 5 mg
  • 0.4% of people on 10 mg
  • 1.2% of people on 15 mg
  • 0.9% of people on placebo

The label then says: "MOUNJARO is not recommended in patients with severe gastroparesis." The patient guide asks you to tell your prescriber if you have "slowed emptying of your stomach (gastroparesis) or problems with digesting food."

Milder stomach side effects are much more common. In the same trial pool, 37.1% to 43.6% of people on Mounjaro had a gastrointestinal side effect, compared with 20.4% on placebo. The label says most nausea, vomiting, and diarrhea happened during dose increases and decreased over time. Postmarketing reports listed in the label include ileus (a stalled bowel), intestinal obstruction, and severe constipation.

What do real-world studies show about gastroparesis risk?

Trials are often too small to catch rare events. So researchers have turned to large insurance-claims databases. Three studies stand out.

  1. The 2023 JAMA research letter. Sodhi and colleagues studied people using semaglutide or liraglutide for weight loss, compared with bupropion-naltrexone. GLP-1 users had a higher risk of gastroparesis (adjusted hazard ratio 3.67, 95% CI 1.15 to 11.90). Tirzepatide was not part of this study. Event counts were small, and the semaglutide group had only 613 people.
  2. The 2026 Annals of Internal Medicine study. Crisafulli and colleagues compared dulaglutide, semaglutide, and tirzepatide in adults with type 2 diabetes. The outcome combined pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation. Tirzepatide versus semaglutide had a hazard ratio of 1.07, and tirzepatide versus dulaglutide had 0.96. Neither difference was significant. The authors concluded the three drugs have similar gastrointestinal safety.
  3. The 2026 Diabetes, Obesity and Metabolism study. Alkabbani and colleagues compared 313,342 matched pairs of GLP-1 based drug users (including tirzepatide) and SGLT-2 inhibitor users. The outcome combined severe constipation, gastroparesis, and bowel obstruction. Rates were 1.02 versus 0.75 per 100 person-years (hazard ratio 1.37). The higher risk held for each part of the outcome and for each drug. The authors stressed the absolute risk was 1% or less.

Put together, these studies suggest a real but small increase in risk. Tirzepatide does not appear riskier than the GLP-1 drugs it is often compared with. All three studies are observational and rely on billing codes, so they cannot prove cause.

Which symptoms should prompt a call to your clinician?

Mild nausea or early fullness after a dose increase is common. The label tells patients to contact their provider for "severe or persistent gastrointestinal symptoms." NIDDK says to seek help right away for:

  • Severe pain or cramping in your abdomen, or sudden sharp pain that does not go away
  • Vomiting for more than an hour
  • Red blood in your vomit, or vomit that looks like coffee grounds
  • Blood sugar that is too high or too low
  • Feeling extremely weak, fainting, trouble breathing, or fever
  • Signs of dehydration, such as extreme thirst, dark urine, or urinating less

The Mounjaro label describes a different warning sign: persistent severe abdominal pain, sometimes spreading to the back. That can point to pancreatitis instead. See our page on Mounjaro pancreatitis warning signs. Dehydration from ongoing vomiting can also harm the kidneys, which the label lists as a separate warning.

Does it go away after you stop Mounjaro?

For most people, the slowing caused by the drug is temporary. The label says the effect is strongest after the first dose and fades with continued use. The label also gives tirzepatide a half-life of about 5 days, so the drug takes several weeks to clear after the last shot.

There is little published data that tracks people after they stop. The large studies above measured risk while people were on treatment, not recovery afterward. If symptoms last well beyond the time the drug should have cleared, your clinician may check for other causes. Diabetes-related nerve damage is the most common one, and it does not depend on the drug.

Do not stop Mounjaro on your own. Your prescriber may hold your dose, slow the increases, or switch you to another treatment. Readers comparing options can find more on the GLP-1 drug class at glp1.md.

The bottom line

Mounjaro slows stomach emptying on purpose, most strongly in the first weeks. Claims studies tie GLP-1 based drugs, tirzepatide included, to a modestly higher risk of gastroparesis and related problems, with an absolute risk around 1% per year or less. The label advises against Mounjaro if you already have severe gastroparesis. Report vomiting, severe pain, or signs of dehydration to your clinician promptly.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber before starting, stopping, or changing Mounjaro, and seek urgent care for severe abdominal pain or persistent vomiting.